symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
PEPG,5.625,0,48825,133950938,0,4.26-20.0,0.205,PepGen Inc.,USD,0001835597,US7133171055,713317105,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.pepgen.com,"PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.",Dr. James G. McArthur Ph.D.,Healthcare,US,54,781-797-0979,245 Main Street,Cambridge,MA,02142,,0,https://financialmodelingprep.com/image-stock/PEPG.png,2022-05-06,False,False,True,False,False
